Stage II colon cancer (CC) encompasses a heterogeneous group of patients with diverse survival experiences: 87% to 58% 5-year relative survival rates for stages IIA and IIC, respectively. While stage IIA patients are usually spared the adjuvant chemotherapy, some of them relapse and may benefit from it; thus, their timely identification is crucial. Current gene expression signatures did not specifically target this group nor did they find their place in clinical practice. Since processes at invasion front have also been linked to tumor progression, we hypothesize that aside from bulk tumor features, focusing on the invasion front may provide additional clues for this stratification. A retrospective matched case-control collection of 39 stage IIA microsatellite-stable (MSS) untreated CCs was analyzed to identify prognostic gene expression-based signatures. The endpoint was defined as relapse within 5 years vs. no relapse for at least 6 years. From the same tumors, three different classifiers (bulk tumor, invasion front, and constrained baseline on bulk tumor) were developed and their performance estimated. The baseline classifier, while the weakest, was validated in two independent data sets. The best performing signature was based on invasion front profiles [area under the receiver operating curve (AUC) = 0.931 (0.815-1.0)] and contained genes associated with KRAS pathway activation, apical junction complex, and heme metabolism. Its combination with bulk tumor classifier further improved the accuracy of the predictions.

Central European Institute of Technology Masaryk University Brno Czechia

Department of Biology Faculty of Medicine Masaryk University Brno Czechia

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czechia

RECETOX Faculty of Science Masaryk University Brno Czechia

Zobrazit více v PubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.21492 PubMed DOI

Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, et al. . Validation study of a quantitative multigene reverse transcriptase–polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. JCO. (2011) 29:4611–9. doi: 10.1200/JCO.2010.32.8732 PubMed DOI

Kopetz S, Tabernero J, Rosenberg R, Jiang Z-Q, Moreno V, Bachleitner-Hofmann T, et al. . Genomic classifier coloPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors. Oncol. (2015) 20:127–33. doi: 10.1634/theoncologist.2014-0325 PubMed DOI PMC

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, et al. . Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in cancer and leukemia group B 9581 (Alliance). JCO. (2016) 34:3047–53. doi: 10.1200/JCO.2015.65.4699 PubMed DOI PMC

Pagès F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, et al. . International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. (2018) 391:2128–39. doi: 10.1016/S0140-6736(18)30789-X PubMed DOI

Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. JCO. (2010) 28:264–71. doi: 10.1200/JCO.2009.24.0952 PubMed DOI PMC

Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, et al. . Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. (2017) 28:1023–31. doi: 10.1093/annonc/mdx052 PubMed DOI PMC

Taieb J, Karoui M, Basile D. How I treat stage II colon cancer patients. ESMO Open. (2021) 6(4):100184. doi: 10.1016/j.esmoop.2021.100184 PubMed DOI PMC

Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. . Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2020) 31:1291–305. doi: 10.1016/j.annonc.2020.06.022 PubMed DOI

Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, et al. . Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and β-catenin. Cells Tissues Organs. (2005) 179:56–65. doi: 10.1159/000084509 PubMed DOI

Bronsert P, Enderle-Ammour K, Bader M, Timme S, Kuehs M, Csanadi A, et al. . Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface: 3D cancer-host interface. J Pathol. (2014) 234:410–22. doi: 10.1002/path.4416 PubMed DOI

Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. . Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. (2000) 124:979–94. doi: 10.5858/2000-124-0979-PFICC PubMed DOI

Graham RP, Vierkant RA, Tillmans LS, Wang AH, Laird PW, Weisenberger DJ, et al. . Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort. Am J Surg Pathol. (2015) 39:1340–6. doi: 10.1097/PAS.0000000000000504 PubMed DOI PMC

Zlobec I, Lugli A. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol. (2009) 15:5898–906. doi: 10.3748/wjg.15.5898 PubMed DOI PMC

Kahlert C, Lahes S, Radhakrishnan P, Dutta S, Mogler C, Herpel E, et al. . Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro . Clin Cancer Res. (2011) 17:7654–63. doi: 10.1158/1078-0432.CCR-10-2816 PubMed DOI

Martin B, Grosser B, Kempkens L, Miller S, Bauer S, Dhillon C, et al. . Stroma AReactive invasion front areas (SARIFA)-A new easily to determine biomarker in colon cancer-results of a retrospective study. Cancers. (2021) 13(19):4880. doi: 10.4324/9781003101857 PubMed DOI PMC

Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, et al. . Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. (2015) 12:115–21. doi: 10.1038/nmeth.3252 PubMed DOI PMC

Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. (2010) 26:2363–7. doi: 10.1093/bioinformatics/btq431 PubMed DOI PMC

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. . Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. (2005) 102:15545–50. doi: 10.1073/pnas.0506580102 PubMed DOI PMC

Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database hallmark gene set collection. Cell Syst. (2015) 1:417–25. doi: 10.1016/j.cels.2015.12.004 PubMed DOI PMC

Kennedy RD, Bylesjo M, Kerr P, Davison T, Black JM, Kay EW, et al. . Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. JCO. (2011) 29:4620–6. doi: 10.1200/jco.2011.35.4498 PubMed DOI

Xu X, Wu Y, Yi K, Hu Y, Ding W, Xing C. IRF1 regulates the progression of colorectal cancer via interferon−induced proteins. Int J Mol Med. (2021) 47:104. doi: 10.3892/ijmm.2021.4937 PubMed DOI PMC

Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, et al. . Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res. (2012) 18:4753–63. doi: 10.1158/1078-0432.CCR-11-3210 PubMed DOI PMC

Jones RP, Sutton PA, Evans JP, Clifford R, McAvoy A, Lewis J, et al. . Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. (2017) 116:923–9. doi: 10.1038/bjc.2017.37 PubMed DOI PMC

Popovici V, Budinska E, Bosman FT, Tejpar S, Roth AD, Delorenzi M. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. BMC Cancer. (2013) 13:439. doi: 10.1186/1471-2407-13-439 PubMed DOI PMC